ARTICLE | Company News
Immunomedics, Nycomed deal
July 4, 2011 7:00 AM UTC
Immunomedics received a $10 million milestone payment from Nycomed under a 2008 deal granting Nycomed exclusive, worldwide rights to develop and commercialize subcutaneous veltuzumab for non-cancer i...